Bruderman Asset Management’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
– Sell
-3,192
Closed -$282K – 112
2019
Q3
$282K Buy
3,192
+134
+4% +$12K 0.07% 105
2019
Q2
$279K Sell
3,058
-1,083
-26% -$91.7K 0.07% 97
2019
Q1
$398K Sell
4,141
-368
-8% -$33K 0.09% 100
2018
Q4
$387K Buy
4,509
+950
+27% +$82.5K 0.1% 94
2018
Q3
$307K Sell
3,559
-1,998
-36% -$165K 0.07% 98
2018
Q2
$420K Sell
5,557
-3,081
-36% -$237K 0.1% 96
2018
Q1
$698K Sell
8,638
-270
-3% -$22.9K 0.17% 86
2017
Q4
$748K Sell
8,908
-1,340
-13% -$113K 0.19% 80
2017
Q3
$880K Sell
10,248
-33,031
-76% -$2.78M 0.23% 74
2017
Q2
$3.61M Sell
43,279
-36,292
-46% -$2.87M 0.96% 33
2017
Q1
$5.91M Sell
79,571
-5,971
-7% -$444K 1.71% 20
2016
Q4
$6.23M Sell
85,542
-2,681
-3% -$194K 1.88% 18
2016
Q3
$6.97M Sell
88,223
-716
-0.8% -$58.2K 2.08% 14
2016
Q2
$7.34M Buy
88,939
+79,512
+843% +$6.13M 2.3% 13
2016
Q1
$683K Buy
9,427
+9,065
+2,504% +$688K 0.24% 73
2015
Q4
$31K Hold
362
– – 0.01% 252
2015
Q3
$33K Buy
362
+132
+57% +$13.1K 0.01% 241
2015
Q2
$23K Hold
230
– – 0.01% 289
2015
Q1
$23K Hold
230
– – 0.01% 284

Other funds holding NVS

Bruderman Asset Management's NVS Position: Q4 2019 in Review

Bruderman Asset Management sold out of Novartis (NVS) in Q4 2019, closing a stake of 3,192 shares — an estimated $282K sold.

Bruderman Asset Management first reported a position in NVS in Q1 2015 and held it in 19 quarters. The position peaked at $7.34M in Q2 2016. 1,171 funds tracked by Wall St. Rank hold NVS as of Q4 2019.

  • Bruderman Asset Management reported no remaining Novartis position as of Q4 2019 after selling out during the quarter.
  • Bruderman Asset Management sold 3,192 Novartis shares in Q4 2019, an estimated $282K.
  • Bruderman Asset Management first reported a position in Novartis in Q1 2015 and held it in 19 quarters.
  • Bruderman Asset Management's Novartis position peaked at $7.34M in Q2 2016.
  • 1,171 funds tracked by Wall St. Rank held Novartis as of Q4 2019.

Based on Bruderman Asset Management's 13F filing for Q4 2019, filed 13 Feb 2020.